Company*
(Country; Symbol)		 Company*
(Country; Symbol)		 Type/Product Area Terms/Details (Date)
Alfacell Corp. (Canada; ACEL) Scientific Protein

Laboratories LLC*

 Purchase and supply agree-

ment for the commercial

production of Onconase		 Onconase is in a Phase IIIb trial for un-

resectable malignant mesothelioma (1/18)
Althea Technologies Inc.* Quintessence Biosciences Inc.* Contract agreement to produce QBI-139, which has demonstrated efficacy against a range of solid tumors in cancer models Althea will provide protein production, purification and aseptic filling services to produce the clinical trial materials (2/12)
Anthera Pharmaceuticals Inc.* Albemarle Corp. (NYSE:ALB) and Patheon Inc. (PK:PNHNF) Manufacturing agreements for the large-scale clinical production of Varespladib for Phase III trials and a new drug application submission to the FDA Albemarle will be responsible for process optimization and manufacturing, and Patheon will be responsible for finished tablet production (1/31)
Clinical Data Inc. (CLDA) Affymetrix Inc. (AFFX) Marketing agreement for a new drug metabolism service using the Affy-metrix Drug Metabolizing Enzymes and Transporter Early Access solution Cogenics and Epidauros Biotechnologie AG, both subsidiaries of Clinical Data Inc., will offer the DMET services globally, with limited exclusivity in Europe (1/24)
CombiMatrix Corp. (CBMX) Clarient Inc. (CLRT) Partnership to market and sell a genomics-based cancer test called HemeScan related to the treatment of chronic lymphocytic leukemia and other cancers The test will be marketed by Clarient to pathologists, oncologists and patients (1/31)
CSL Ltd.* (Australia) Celltrion Inc.* (South Korea) Contract manufacturing agreement for Celltrion to supply the monoclonal antibody CSL 360 CSL 360 is undergoing a Phase I trial for acute myeloid leukemia (1/10)
Emergent BioSolutions (NYSE:EBS) Ninebio Sdn. Bhd.* (Malaysia) Joint venture in Malaysia to create a biologics infra-structure and supply biodefense countermeasures, including BioThrax, and other medical and complementary products and services to the government of Malaysia The venture also will seek to supply products and services to other member countries of the Organization of the Islamic Conference and other countries within Asia (1/24)
Genmab A/S (Denmark; CSE: GEN) PDL BioPharma Inc. (PDLI) Agreement for Genmab to buy PDL's manufacturing facility for $240M The deal includes the land, equipment and access to a leased space housing a development lab (2/21)
GenVec Inc. (GNVC) Cobra Biomanufacturing plc (UK; LSE:CBF) Manufacturing development agreement for TNFerade, an adenovector GenVec is developing TNFerade for use in combination with radiation and/or chemotherapy for the treatment of various cancers (1/24)
ImmuneRegen BioSciences (subsidiary of IR BioSciences Holdings Inc.; OTC BB:IRBO) Celgene Cellular Therapeutics (subsidiary of Celgene Corp.; CELG) Material transfer agreement under which ImmuneRegen will ship its potential therapeutic Homspera to CCT for testing CCT will explore Homspera's impact when used in conjunction with CCT's human stem/progenitor cell active products and developmental candidates (1/23)
Invitrogen Corp. (IVGN) IMBcom Proprietary Ltd.* (affiliated with the University of Queensland's holdings company) Exclusive license deal to commercialize non-coding RNA content predicted by a algorithm and experimentally validated by the Australian university Invitrogen will commercialize those sequences over the next few years (1/17)
Invitrogen Corp. (IVGN) Luminex Corp. (LMNX) Expanded licensing and supply agreement for Luminex's xMAP Technology for use in multiplexed assays Further terms were not disclosed (2/12)
Laureate Pharma Inc.* Arius Research Inc. (Canada;TSX:ARI) A cGMP contract manufacturing agreement Laureate will produce Arius' IgG1 human-ized antibody; the program targets a marker linked to aggressive cancers (1/31)
PamGene International BV* (the Netherlands) Invitrogen Corp. (IVGN) Agreement to co-market Invitrogen's Nuclear Hormone Receptor proteins and Lantha-screen assay technology with PamGene's portfolio of microarray-based Nuclear Hormone Receptor screening tools Financial terms were not disclosed (1/15)
Pinnacle Biologics* MedImmune Inc. (LSE:MDI) Exclusive distribution agreement for Ethyol (amifostine) The agreement grants Pinnacle Biologics exclusive Ethyol marketing authorization and certain licenses and distribution rights in Western Europe, Turkey and Israel (2/19)
Plasticell Ltd.* (UK) Axordia Ltd.* (UK) Agreement to exploit and market a panel of six human embryonic stem cell lines Plasticell obtained a right to make and sell the hESC lines Shef 1, 2, 4, 5, 7 and 8; terms of the licensing agreement were not disclosed (1/14)
Third Wave Technologies (TWTI) Inverness Medical Iberica (Spain; affiliate of Inverness Medical Innovations; AMEX:IMA)

Distribution agreements for the firm's human papillomavirus screening product, which is used for routine screening for cervical cancer Inverness Medical Iberica will be the distributor for Spain and Portugal, while four distributors have been secured in Italy (1/8)
Valeant Pharmaceuticals International (NYSE:VRX) Three Rivers Pharmaceuticals LLC* Agreement under which Valeant has sold U.S. and Canadian rights to hepatitis C drug Infergen (interferon alfacon-1) Valeant will receive about $70.8M in cash upon closing, and up to $20.5M in two noncontingent payments over the following 18 months (12/20)
Notes:

* Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market. AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSX = Toronto Stock Exchange.